Christophe Benoist, MD, PhD
Christophe Benoist is a molecular immunologist, currently the Morton Grove-Rasmussen Chair in Immunohematology at Harvard Medical School. He initially trained in France, obtaining an M.D. from the Université de Paris – Bichat/Beaujon and a Ph.D. with P. Chambon at the Université Louis Pasteur, Strasbourg, followed by postdoctoral studies at Stanford University. He returned to France in 1983 to establish an Immunology research laboratory at the IGBMC in Strasbourg, together with Dr. Diane Mathis. In 1999 they moved to Harvard Medical School, first at the Joslin Diabetes Center, then at the Department of Microbiology and Immunobiology. He is also an Associate Faculty Member of the Broad Institute, and Affiliated Faculty of the Harvard Stem Cell Institute. He plays a leadership role in the Immunological Genome Project consortium, and serves or has served on the Advisory Boards of the Jackson Laboratory, Centre d’Immunologie de Marseille-Luminy, the Walter Elisa Hall Institute and Institut Pasteur. He has served as SAB member or academic founder of Peptimmune, Phenomix, Tolerex, Tempero, Delinia and Celgene. Dr. Benoist was elected to the French Académie des Sciences in 1999, and to the US National Academy of Sciences in 2005.
The Benoist/Mathis lab works in the fields of T cell tolerance and autoimmunity, attempting to decipher the molecular and cellular mechanisms that control T cell differentiation, the acquisition and maintenance of immunological tolerance or its failure in autoimmune diseases. The lab has historically generated a number of important mouse models of tolerance and autoimmunity, made seminal contributions to the understanding of gene regulation in the immune system, the role of the Aire gene in immunological tolerance, the impact of Tregulatory cells in the control of immune and inflammatory responses. Current investigations use a broad range of “Systems Immunology” approaches to decipher immunoregulation in mice and humans, and the microbiome’s influence on these processes.